Found 23 articles for: "Plaque Psoriasis"
Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreStudy of Adjuvant Sensitive-Skin Cleansing and Moisturizing Regimen in Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 739 | Copyright © August 2025
Read MoreHalobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance
August 2025 | Volume 24 | Issue 8 | Original Article | 752 | Copyright © August 2025
Scalp involvement in plaque psoriasis is accompanied by itching and scaling that reduce quality of life and exacerbate psoriatic-associated hair loss. Challenges for the topical treatment of scal...
Read MoreDeucravacitinib With Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis
August 2025 | Volume 24 | Issue 8 | Original Article | 744 | Copyright © August 2025
Background: To assess the effectiveness, safety, and quality of life in patients who received topical calcipotriene/betamethasone dipropionate (C/BD) foam added to oral deucravacitini...
Read MoreTwo-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients
August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025
Objective: The study objective was to compare long-term treatment persistence between patients initiating guselkumab vs 3 commonly prescribed biologics in the United States.Read MoreClinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis
June 2025 | Volume 24 | Issue 6 | Original Article | 590 | Copyright © June 2025
Background: Hyperkeratotic psoriatic plaques, characterized by considerable elevation and scaling, present treatment challenges with topical therapy. This post hoc analysis of tw...
Read MoreSelective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 645 | Copyright © August 2024
Members of the Janus kinase (JAK) superfamily, comprising tyrosine kinase 2 (TYK2) and JAK1, JAK2, and JAK3, mediate signaling by cytokines (eg, interleukin [IL]-23) involved in psoriasis pathoge...
Read MoreTildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real-world effectiveness a...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MorePreference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 607 | Copyright © August 2024
Background: The combined use of topical calcipotriol/betamethasone dipropionate (Cal/BDP) is commonly used and demonstrated to be effective for the management of psoriasis and is...
Read MoreReal-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024
Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-...
Read MoreRapid Remission of Plaque Psoriasis With Bimekizumab Treatment
August 2024 | Volume 23 | Issue 8 | Features | 694 | Copyright © August 2024
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recentl...
Read MoreFirst Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
March 2024 | Volume 23 | Issue 3 | Case Reports | 192 | Copyright © March 2024
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. Th...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreTildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis
August 2023 | Volume 22 | Issue 8 | Original Article | 766 | Copyright © August 2023
Background: This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients.A Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreSingle-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 864 | Copyright © August 2022
The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreCharacteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database
October 2021 | Volume 20 | Issue 10 | Features | 1127 | Copyright © October 2021
Guselkumab is approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis. However, characteristics of patients initiating guselkumab in a real-world setting ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
